These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29194647)

  • 1. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.
    Amikura K; Akagi K; Ogura T; Takahashi A; Sakamoto H
    J Surg Oncol; 2018 Mar; 117(4):745-755. PubMed ID: 29194647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
    Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation Status of
    Kawaguchi Y; Kopetz S; Newhook TE; De Bellis M; Chun YS; Tzeng CD; Aloia TA; Vauthey JN
    Clin Cancer Res; 2019 Oct; 25(19):5843-5851. PubMed ID: 31221662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
    Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
    Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.
    Chun YS; Passot G; Yamashita S; Nusrat M; Katsonis P; Loree JM; Conrad C; Tzeng CD; Xiao L; Aloia TA; Eng C; Kopetz SE; Lichtarge O; Vauthey JN
    Ann Surg; 2019 May; 269(5):917-923. PubMed ID: 28767562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
    Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
    Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?
    Allard MA; Saffroy R; de la Maisonneuve PB; Ricca L; Bosselut N; Hamelin J; Lecorche E; Bejarano MA; Innominato P; Sebagh M; Adam R; Morère JF; Lemoine A
    Target Oncol; 2015 Sep; 10(3):415-21. PubMed ID: 25420993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer.
    Yaeger R; Cowell E; Chou JF; Gewirtz AN; Borsu L; Vakiani E; Solit DB; Rosen N; Capanu M; Ladanyi M; Kemeny N
    Cancer; 2015 Apr; 121(8):1195-203. PubMed ID: 25491172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
    Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.
    Koch C; Schmidt N; Winkelmann R; Eichler K; Pession U; Bechstein WO; Zeuzem S; Waidmann O; Trojan J
    Digestion; 2018; 98(4):263-269. PubMed ID: 30130797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
    Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
    Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of various RAS codon mutations and prognostic outcomes of patients with colorectal liver metastases after hepatectomy.
    Wu XG; Liu W; Wang YY; Wang K; Xing BC
    Cancer Med; 2024 Oct; 13(19):e70168. PubMed ID: 39377605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.
    Zimmitti G; Shindoh J; Mise Y; Kopetz S; Loyer EM; Andreou A; Cooper AB; Kaur H; Aloia TA; Maru DM; Vauthey JN
    Ann Surg Oncol; 2015 Mar; 22(3):834-842. PubMed ID: 25227306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
    Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.